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Abstract 
 
 
New methodology has been utilized to provoke or increase targeted metabolic pathways 
in microbes.  The low hanging fruit of natural products has been discovered over the last 50 
years.  To continue finding new metabolites to be used as possible drug candidates, methodology 
development such as those proposed herein are necessary.  This methodology uses extracts from 
known pathogenic bacteria to elicit production of latent biosynthetic pathways from 
environmental bacterial isolates that may be active against the original pathogenic strains.  A 
new compound, MAV-1 (1) of the diketopiperazine family (Figure 1) was isolated and identified 
utilizing these techniques.  The structure of MAV-1 (1) was defined by a combination of mass 
spectroscopy (MS) and nuclear magnetic resonance (NMR) spectroscopy.  Discovery of MAV-1 
(1), a possible precursor to other known compounds, demonstrates the continuing utility of 
microbial sources with new chemodiversity. 
 
Figure 1:  New diketopiperazine MAV 1 (1) isolated using new methodology. 
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Introduction 
 
Bacteria generation times may be as short as ten minutes
1 
giving the rapidly reproducing 
organisms an evolutionary edge over humans in terms of chemical attack and defense.  Humans 
have developed antibiotics to treat microbial infections.  However, every antibiotic released finds 
clinically significant microbes that are resistant.  As the antibiotic is used to treat infections the 
frequency of resistant organisms climbs
2
 making once highly potent antibiotics less useful in the 
clinical setting.  Currently the worst culprits of human infection also having high levels of 
antimicrobial resistance are remembered using the acronym ESKAPE (Enterococcus sp., 
Staphylococcus aureus, Klebsiella sp., Acinetobacter baummannii, Pseudomonas aeruginosa, 
and Enterobacter sp.).  According to the Center for Disease Control, these organisms are 
responsible for two thirds of all health care-associated infections (HAIs).
3
 
Natural products chemistry is a major contributor to the discovery of new compounds to 
combat resistant microbes.  A high number of antibiotic scaffolds and their analogs have been 
discovered from natural products chemistry and it is assumed more exist and await elucidation of 
their structures.
4,5
  Even armed with this information fewer antibiotics are being released from 
natural products programs than at any time in the last 50 years.
6
 
 We have investigated multiple techniques in the attempt to elicit production of new 
chemistry from environmental microbes.  The basic procedure of growing microbes, extracting 
compounds and testing for activity does generate activity in the form of hits, but other 
methodologies may increase titers and elicit new scaffolds and analogs.
7
  In an attempt to 
2 
 
activate (or further activate) metabolite pathways responsible for the production of useful 
chemicals, epigenetic modification of the microbes was utilized to build upon the basic 
approach.  While this experiment did result in an increased hit rate against methicillin-resistant 
Staphylococcus aureus (MRSA), the very methodology was designed to be a non-specific 
enhancer of natural product production, not specific to antimicrobial responses.
7
 A procedure 
designed to elicit antimicrobial responses was then put into practice in the form of a live-live co-
culture experiment.  This experiment was designed to simulate natural conditions in which the 
microbes interact with interspecies competition.
8 
Secondary metabolites arising from this competition that have an anti-microbial effect 
must be measured.  The Kirby-Bauer disk diffusion bio-assay is a widely accepted method for 
determining antimicrobial bio-activity.  The Kirby-Bauer disk diffusion assay was originally 
developed to test resistance/susceptibility of bacteria to different antibiotics.  Following 
incubation any chemical that either kills the bacteria or inhibits growth generates a circular zone 
of inhibition where no (or few) bacterial colonies are capable of growing.  Comparison of known 
antibiotic zones tells medical professionals how resistant the particular organism is to that 
particular drug.
9
 
Natural microbial responses to competing microbes can involve the creation and release 
of secondary metabolites.  A dead-live study involving dead pathogenic bacteria metabolites and 
live environmental bacteria from a variety of sources provides a method to elicit higher hit rates, 
potentially leading to an increased number of marketable antibiotics.  In nature, bacteria generate 
defensive chemicals to prevent encroachment by competing organisms.  Stimulation of these 
antimicrobial responses may come from physical interaction between competing microbes, or the 
interaction between the microbial cell and foreign chemical metabolites within the environment.  
3 
 
The latter possibility seems more likely as physical interaction between cells cannot be assured 
among an entire population, and this was the basis for this dead-live study.
10 
 In this project it was hypothesized that the presence of secondary metabolites from one 
species of microbe would result in an increase in anti-microbial compounds.  It was expected that 
this was a natural response in the field environment and that it could be duplicated reliably in a 
lab environment.  It was believed this would result in an increase in the amount and number of 
isolated anti-microbial compounds, thereby increasing the usefulness of bacteria as sources of 
therapeutics.   
4 
 
 
 
 
 
Materials and Methods 
 A reproducible method of eliciting an antimicrobial response from environmentally 
sourced bacteria is key to the success of this experimentation method.  The steps involved in this 
process are the generation of a pathogen metabolite extract, proper mixing via broth culture with 
a test microbe, isolation and identification of natural products generated by the culture, and, 
finally, a comparison with existing publications. 
To generate a pathogen metabolite solution the following steps were taken:  Methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus sp., and 
Pseudomonas aeruginosa were each grown separately in tryptic soy broth (TSB, composition:  
17.0 g/L pancreatic digest of casein, 3.0 g/L papaic digest of soybean, 2.5 g/L sodium chloride, 
and 2.5 g/L dextrose) at room temperature.  Following five days of growth these organisms were 
frozen, lyophilized, and extracted using methanol.  The extracted material was solvated using 
1/10
th
 the initial culture volume then filtered (0.2 μm) to remove the bacterial cells.  While 
fragments of lysed cells could still be present in the pathogen metabolite solution, this method 
reduced the possibility of test bacteria reacting to physical contact between themselves and 
pathogenic bacteria.     
Bacteria were required to test against.  These bacterial cultures were harvested from 
collection sites such as Palmer Station, Antarctica, Long Key, Florida and various mangroves 
from multiple regions of Florida.  These isolates came from soil sediment, plants and water 
columns.  Organisms were isolated on Tryptic Soy Agar (TSA, composition:  17.0 g/L pancreatic 
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digest of casein, 3.0 g/L papaic digest of soybean, 2.5 g/L sodium chloride, 2.5 g/L dextrose, and 
15 g/L grade A agar) then grown in 100 mL or 250 mL cultures of TSB.  Five days into the 
growth cycle 5 mL of pathogen metabolite solution was added.  On the seventh day the cells 
were subcultured onto TSA and frozen.  Subculturing was compared to original cells to ensure 
purity as it was possible for the pathogen to overtake the isolated organism if any pathogen 
survived extraction via methanol.   
Following freezing the broth was lyophilized.  The dried material underwent exhaustive 
extraction with methanol.  All extracts were gravity filtered into a pre-weighted 250 mL round 
bottom flask.  The extract was dried under air and the final mass recorded.  Three to four times 
the extract mass of silica was added with 100 mL of methanol.  This was mixed and concentrated 
via rotovap.  The silica/extract powder was fractionated by medium pressure liquid 
chromatography (MPLC) using 50/50 hexane/ethyl acetate to 100% ethyl acetate, then to 25/75 
ethyl acetate/methanol to ensure maximum recovery of material.  Similar fractions were 
combined using UV absorbance (wavelengths 254 nm and 280 nm) and evaporative light 
scattering detection (ELSD) and air dried.  Fractions were transferred with appropriate solvent 
into pre-weighed 20 mL scintillation vials and again dried under air.   
Methanol was added to each fraction to yield 50 mg/mL solutions.  These fractions were 
adequately solvated, then 20 μL (1 mg of fraction) was transferred to blank paper disks (6 mm 
diameter), and Kirby-Bauer assays performed (see below). 
Kirby-Bauer disk diffusion assays were performed to determine whether activity against 
the target pathogens existed within the fraction.  The pathogenic bacteria were streaked across a 
plate so as to provide an even lawn of growth following incubation.  Prior to incubation, paper 
disks impregnated with compounds or fractions of interest were spaced evenly across this lawn 
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and incubated at 37˚C for 24 hours.  In the case of this study the identity of the potential 
antibiotic was unknown and so no comparison of zone of inhibition could be used to determine 
the efficacy of the unknown drug.  For this reason any zone of inhibition was considered to be a 
“hit” within the fraction.  The active component could potentially make up a very small 
percentage of the overall fraction and enough of the active component needed to be present to 
ensure visibility of its action.  Using large masses of the each fraction for Kirby-Bauer testing 
became impractical for two reasons.  First, a limited mass of each fraction was usually collected 
due to the small sample sizes.  Second, most compounds are toxic in large enough quantities.  If 
too large a mass was used there would have been many false or weakly positives that would have 
been worked up without justification or promise.  Taking into consideration all of the above 
factors the Baker lab has established 1 mg of each fraction to be adequate for this stage of hit 
testing. 
Isolation schemes for hit follow up compounds followed bioactivity as determined by 
Kirby-Bauer.  Each active fraction underwent reverse phase MPLC.  After fractions were 
combined and tested again, the active fraction underwent a second round of normal phase MPLC 
(using a sharper polarity range) for a better separation. 
HPLC was performed to obtain final compound purification.  Several analytical HPLC 
analyses were performed to insure adequate separation of compounds into fractions that could 
undergo bioassay.  When all lead compounds within the active fraction were fully resolved via 
HPLC, positive mode mass spectroscopy was utilized to determine the individual compounds 
formula. Following isolation, bioassay could determine which compound was active and, if 
sufficient mass of the compound remained, efforts were put forth to elucidate the structure of the 
7 
 
active compound via 1D and 2D NMR spectroscopy, as well as comparison to known compound 
databases. 
8 
 
 
 
 
 
Results and Discussion 
This project alone has isolated more than 300 individual bacterial organisms from regions 
around the world.  These are the organisms that have been obtained from their environments and 
purified onto isolation plates to be used at a future date.  Each of these has a glycerol stock 
maintained in a -80°C freezer as well as an isolation plate that is replated every 6 months to 
ensure organism viability.  These steps insured a diverse population used to conduct the 
remainder of the study.   
Following isolation 67 of these organisms underwent 100 mL culture as outlined in the 
methods section.  Of note, the sample identification has been placed into shorthand to limit the 
amount of writing per 20 mL vial.   
Table 1:  Sample ID’s were converted to a documented lab shorthand.  This chart is an example of the 
documentation method used during this project. 
Number 
Sample 
ID 
Crude 
Mass 
Final 
Mass 
% 
recovery Active? 
1 k48 1.902 0.59 31.0 - 
2 k31A 2.328 1.498 64.3 + 
3 K49 8.495 4.311 50.7 - 
4 K61 2.073 1.157 55.8 - 
5 V97 2.164 1.242 57.4 + 
6 V84 2.965 1.1393 38.4 + 
7 K78 2.802 0.674 24.1 - 
8 K32 1.608 0.876 54.5 + 
9 K47 1.586 0.867 54.7 - 
10 V82 2.073 0.874 42.2 - 
 
 
Following recovery of the extract, each extract then underwent MPLC separation.  For 
example, K31a produced the following MPLC chromatogram shown in Figure 2. 
9 
 
Figure 2.  MPLC chromatogram of K31a and identification of the 10 fractions. 
 Fractionation points are arbitrary for each fraction, though UV and ELSD signals define 
the major compounds.  Minor compounds can easily be spread between multiple fractions as 
their signals may be too small to detect.   
Fractions from Table 2 were further screened for activity.  Of note, there is no correlation 
between height/width (or even presence) of either an ELSD or UV peak and mass of material 
within the fraction.    
Antimicrobial activity testing via Kirby-Bauer assay were performed in the Shaw 
laboratory at University of South Florida. Each fraction was tested against two gram positive 
organisms and two gram negative organisms; Staphylococcus aureus, Enterococcus sp., 
Klebsiella sp., and Pseudomonas aeruginosa respectively.  Figure 3 shows the exact well 
position for the Kirby-Bauer disk, the sample and MPLC fraction to be tested, and the amount of 
solvent required to obtain the correct concentration for testing.   
10 
 
Table 2.  Fractions collected from BGC11-43-B1-A (K31a).  Uniform concentrations of fractions are necessary to 
reduce errors in testing. 
Fraction 
# 
Sample 
WT 
mL for 50 
mg/mL 
mL for 
30mg/mL 
1 0 N/A N/A 
2 0.008 0.16 0.267 
3 0.005 0.1 0.167 
4 0.026 0.52 0.867 
5 0.082 1.64 2.733 
6 0.128 2.56 4.267 
7 0.241 4.82 8.033 
8 0.18 3.6 6 
9 0.652 13.04 21.733 
10 0.176 3.52 5.867 
 
Figure 4 shows a Kirby-Bauer assay plate after 24 hours of incubation.  Two of the tested 
fractions were clear positives with obvious zones of inhibition.  These active fractions were 
chosen to be worked up further to identify the individual compound responsible for the inhibition 
of the pathogen. 
Table 3.  Rows A and E from an example plate map.   
Row Number Sample Fraction  Row Number Sample Fraction 
A 1 V136 1  E 1 V80 1 
A 2 v136 2  E 2 v80 2 
A 3 v136 3  E 3 V80 3 
A 4 v136 4  E 4 V80 4 
A 5 v136 5  E 5 V80 5 
A 6 v136 6  E 6 V80 6 
A 7 v77 1  E 7 V80 7 
A 8 v77 2  E 8 V80 8 
A 9 v77 3  E 9 v61 1 
A 10 v77 4  E 10 v61 2 
A 11 v77 5  E 11 v61 3 
A 12 v77 6  E 12 v61 4 
 
11 
 
 
Figure 3.  An example Kirby-Bauer plate with clear zones of inhibition. 
 Among fractions found to be active in screening, those with the most physical mass were 
then carried forward to HPLC purification until compounds were isolated, or until insufficient 
mass to continue isolation and identification remained.  MAV-1 (1) arose from K31a and will 
continue to be the focus of this paper.  K31a was active against both Staphylococcus aureus and 
Pseudomonas aeruginosa, but failed to affect either Enterococcus sp. or Klebsiella sp.  This is 
important because the compounds present inhibited both gram positive and gram negative 
organisms, but did not cause universal inhibition, a likely sign of cytotoxicity.  Of all the active 
isolates, this was the only one with this activity profile. 
K31a had insufficient mass to advance to purification of individual components, so a five 
liter culture was produced using the same techniques as before.  The active fraction was 
partitioned between butanol/water and it was found that the bioactive compound remained in the 
butanol partition.  Both partitions were then dried.  Figure 5 shows the work up scheme of the 5 
L culture. 
With the large scale culture every fraction had substantially more mass (the active 
fraction five had almost a gram of material as opposed to the 80 mg found in the small scale 
12 
 
culture).  Multiple compounds were found in the active fraction, and these were isolated using 
HPLC instrumentation. 
Figure 6 demonstrates how complex the MPLC fractions can actually be.  The detector in 
Figure 5 was a single quadrupole mass spectrometer.  This clearly demonstrated multiple 
separate compounds within the fraction, most of which had insufficient mass to work to 
completion.   
Of the compounds with sufficient mass for work up, MAV-1 (1) was the only new 
compound.  The compound was almost discarded because of its similarity to the 
13
C NMR 
spectra (seen in Figures 7 and 8) belonging to the following two compounds ((2) and (3)), also 
found within fractions from the same organism. 
 
Figure 4.  Fractionation scheme of the 5 L culture of K31a.  Fractions not listed did not have bioactive 
compounds present. 
13 
 
 
 
Figure 5.  Purification scheme of MPLC fraction 5, K31a 5 L culture.  
  
 
Figure 6.  Compounds 2 and 3, known diketopiperazines found in the active fraction of K31a. 
 
 
Figure 7.  13C NMR spectrum of (2) found in the active fraction of K31a. 
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Figure 8.  13C NMR spectrum of (3) found in the active fraction of K31a. 
 
 Figure 9 shows the 
13
C NMR spectrum of 
 
compounds (2) and (3) while Figures 10 and 
11 are the 
13
C NMR spectra that were collected during this research for the same.  Table 4 shows 
a comparison of the 
13
C NMR spectra that were obtained in this project to previously reported 
data while Table 5 is a similar comparison between MAV-1 (1) and compounds (2) and (3).
11,12
  
This, combined with matching mass spectroscopy data clearly demonstrates that compounds (2) 
and (3) are the same as those discovered previously.
11 
Figure 9 and Table 5 clearly demonstrates the striking similarities between the 
combination of compounds (2) and (3) and MAV-1 (1).  Of the 22 carbon signals, 20 of them 
vary by 5 ppm or less.  The remaining two carbons are markedly different, which can easily be 
explained by the additional functional group that links the two diketopiperazines.  The difference 
between the reported two carbon signals (5 and 6) and the values seen in the obtained spectrum 
prevented this compound from being discarded.  Instead, mass spectroscopy was performed 
using a single quadrupole time of flight instrument revealing a mass of 450.2479 g/mol and a 
formula of C22H34N4O6.  The combination of (2) and (3) have a formula quite similar; 
C22H36N4O4.  This demonstrates a net exchange of two oxygen atoms for two hydrogen atoms.   
15 
 
The carbons shifts that were found to be drastically different from reported values are the 
carbons of the N-C-C back bone that bear the proline R group.  As the other carbons match up 
identically, a peroxide bridge between the two carbons linking the diketopiperazines is the only 
logical difference.  A closer look at the 1D and 2D NMR spectra of MAV-1 (1) provides further 
evidence to the final structure. 
Figures 10 and 11 show every 
13
C NMR signal in MAV-1 (1).  These values are reported 
in Table 5 and directly compared to the signals from (2) and (3).   
 
Figure 9.  The 13C NMR spectra of MAV-1 (1) with software suppression of the CDCl3 signal. 
 
 
Figure 10.  An expansion of the 90-180 ppm portion of the 13C NMR spectrum of MAV-1 (1). 
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Figure 11.  An expansion of the 10-65 ppm portion of the 13C NMR spectrum of MAV-1 (1). 
Table 4.  A comparison of diketopiperazines 2 and 3 with previously known compounds. 
Veri 
(2) 
Crews 
(2)     
Veri 
(3) 
Crews 
(3)   
Cyclo 
(Pro-
Ile) 
Cyclo 
(Pro-
Ile) Delta   
Cyclo 
(Pro-
Ile) 
Cyclo 
(Pro-
Ile) Delta 
169.9 169.9 0.0   170.4 171.4 1.0 
165.0 165.1 0.1   166.2 167.1 0.9 
60.5 60.6 0.1   59 59.1 0.1 
58.8 58.9 0.1   53.4 53.4 0.0 
45.1 45.2 0.1   45.5 45.6 0.1 
35.3 35.3 0.0   38.6 38.7 0.1 
28.5 28.6 0.1   28.1 28.2 0.1 
24.0 24.1 0.1   24.7 24.8 0.1 
22.4 22.4 0.0   23.3 22.8 0.5 
15.9 16.0 0.1   22.8 22.8 0.0 
12.1 12.2 0.1   21.2 21.2 0.0 
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Table 5.  A comparison of MAV-1 (1) to compounds 2 and 3. 
Carbon 
# 
MAV-
1 (1) 
Compounds 
(2)+(3) 
Delta 
  
Carbon 
# 
MAV-
1 (1) 
Compounds 
(2)+(3) 
Delta 
1 168.3 170.4 2.1   12 36.6 35.3 1.3 
2 167.4 169.9 2.5   13 33.2 28.5 4.7 
3 166.6 166.2 0.4   14 33.1 28.1 5 
4 166.4 165 1.4   15 24.5 24.7 0.2 
5 96.1 60.5 35.6   16 24 24 0 
6 95.7 59 36.7   17 23.2 23.3 0.1 
7 61.4 58.8 2.6   18 21.3 22.8 1.5 
8 54.3 53.4 0.9   19 19.6 22.4 2.8 
9 45.2 45.5 0.3   20 19.5 21.2 1.7 
10 44.7 45.1 0.4   21 15.8 15.9 0.1 
11 40 38.6 1.4   22 12 12.1 0.1 
 
 Analysis of the 2D NMR data uses Figure 12 to identify the selected carbons.  Table 6 
utilizes an HSQC spectrum (Figure 13) to designate proton-carbon 1-bond direct attachments.  
This information is critical to making assignments using COSY and HMBC spectra. 
18 
 
 
Figure 12.  A numerical breakdown of the carbon atoms found in MAV-1 (1) to assist in structural elucidation. 
 
 
Figure 13.  An HSQC spectrum of MAV-1 (1).  These correlations were used to fill Table 6. 
 
Figure 14 is the actual COSY spectrum.  Table 7 is both a theoretical list of possible 
COSY signals as well as an annotation of those signals actually seen within the spectrum.  
Missing signals fell to close to the axis and were concealed by the high level of noise found in 
that area of the spectrum.  Some signals are reported twice as they were visible within the 
spectrum on both sides of the axis (ideally, all signals should be visible twice within the 
spectrum).  Of the 22 theoretical signals, 12 can be seen, 9 exist in the base line, and 1 that 
should be visible is not though has overlap with an additional signal that may be concealing it. 
19 
 
Table 6.  The direct 1-bond correlations between carbons and protons in MAV-1 (1), carbon assignments, and 
number of attached protons to each carbon as determined by HSQC, DEPT, 
1
H and 
13
C NMR spectra. 
Carbon 
# 
CHx δC δH   
Carbon 
# 
CHx δC δH 
1 3 23.2 0.98, d 
  
12 0 95.7   
2 1 24.5 1.78, m   13 0 166.6   
3 2 40 1.98, dd; 1.62, dd   14 1 54.3 4.26, d 
4 3 21.3 0.97, d   15 0 167.4   
5 1 61.4 4.4, d   16 2 44.7 3.71, dd; 3.71, dd  
6 0 168.3     17 2 19.5 1.97, dd; 1.96, dd 
7 0 96.1     18 2 33.1 2.33, m;  2.31, m 
8 0 166.4     19 1 36.6 2.32, m 
9 2 45.2 3.82, dd; 3.81, dd   20 2 24 1.32, dq; 1.21, dq 
10 2 19.6 2.11, dd; 2.10, dd   21 3 12 0.91, t 
11 2 33.2 2.21, m; 2.20, m   22 3 15.8 1.06, d 
 
  
 
Figure 14.  COSY spectrum of MAV-1 (1) demonstrating 3 bond correlations between adjacent protons. 
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Table 7.  (Left) A theoretical list of COSY signals for MAV-1 (1). (Right) A list of signals noted within the COSY 
spectrum of MAV-1 (1). 
Theoretical COSY Signals 
 
Actual signals noted within the COSY spectrum 
Signal 
# 
Carbon 
# 
Carbon 
# 
δH δH 
 
Signal 
Coordinates 
Corresponding 
Carbons 
Theoretical Signal # 
1 1 2 0.98 1.78 
 
X Y δC δC   
2 4 2 0.97 1.78 
 
6.47 4.27 N-H 14 14 
3 2 3 1.78 1.98/1.62 
 
4.26 6.47 14 N-H 13 
4 3 5 1.98/1.62 4.4 
 
4.37 1.59 5 3 4 
5 9 10 3.82/3.81 2.11/2.1 
 
1.62 4.35 3 5 4 
6 10 11 2.20/2.21 2.11/2.10 
 
2 1.64 3 3 15 
7 18 17 2.33/2.31 1.97/1.96 
 
1.61 1.99 3 2 3 
8 17 16 2.33/2.31 3.71/3.71 
 
1.79 0.97 2 4 or 1 1 and/or 2 
9 14 19 4.26 2.32 
 
0.96 1.76 4 or 1 2 1 and/or 2 
10 19 22 2.32 1.06 
 
1.31 0.91 20 21 12 
11 19 20 2.32 1.32/1.21 
 
0.9 1.31 21 20 12 
12 20 21 1.32/1.21 0.91 
 
4.26 2.31 14 19 9 
13 N-H 5 6.57 4.4 
 
1.21 0.9 20 21 12 
14 N-H 14 6.5 4.26 
 
1.99 4.39 5 3 4 
15 3 3 1.98 1.62 
 
3.78 2.08 9 10 5 
16 9 9 3.82 3.81 
 
2.09 3.77 10 9 5 
17 10 10 2.11 2.1 
 
4.13 1.25 14 20 * 
18 11 11 2.21 2.2 
 
1.27 4.11 20 14 * 
19 16 16 3.71 3.71 
 
1.06 2.32 22 19 10 
20 17 17 1.97 1.96 
 
2.32 1.06 19 22 10 
21 18 18 2.33 2.31 
 
1.32 2.31 20 19 11 
22 20 20 1.32 1.21 
 
* Signal should be visible on HMBC, not COSY 
 
 Table 8 lists the 64 theoretical HMBC signals assuming that MAV-1 (1) represents the 
correct structure.  Table 9 lists the actual HMBC correlations noted in the HMBC spectrum.  
Eighteen theoretical signals were absent; ten of those missing signals had the correlating signal 
present or were present in the COSY spectrum.  Eight signals had no other signal to verify off of, 
and were not present. 
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Table 8.  The theoretical HMBC correlations associated with MAV-1 (1). 
Signal 
# 
Proton 
attached 
to Carbon 
# 
Carbon 
# 
δH δC   
Signal 
# 
Proton 
attached 
to Carbon 
# 
Carbon 
# 
δH δC 
1 1 2 0.98 24.5   33 17 18 1.97/1.96 33.1 
2 1 4 0.98 21.3   34 17 16 1.97/1.96 44.7 
3 1 3 0.98 40   35 16 18 3.71 33.1 
4 2 1 1.78 23.2   36 16 17 3.71 19.5 
5 2 3 1.78 40   37 19 14 2.32 54.3 
6 2 4 1.78 21.3   38 19 15 2.32 166.4 
7 2 5 1.78 61.4   39 19 20 2.32 24 
8 3 1 1.98/1.62 23.2   40 19 21 2.32 12 
9 3 2 1.98/1.62 24.5   41 19 22 2.32 15.8 
10 3 4 1.98/1.62 21.3   42 20 21 1.32/1.21 12 
11 3 5 1.98/1.62 61.4   43 20 14 1.32/1.21 54.3 
12 3 6 1.98/1.62 166.6   44 20 19 1.32/1.21 36.6 
13 4 1 0.97 23.2   45 20 22 1.32/1.21 15.8 
14 4 2 0.97 24.5   46 21 19 0.91 36.6 
15 4 3 0.97 40   47 21 20 0.91 24 
16 5 2 4.4 24.5   48 22 14 1.06 54.3 
17 5 3 4.4 40   49 22 19 1.06 36.6 
18 5 6 4.4 166.6   50 22 20 1.06 24 
19 9 10 3.82/3.81 19.6   51 NH 5 6.57 61.4 
20 9 11 3.82/3.81 33.2   52 NH 3 6.57 40 
21 10 9 2.11/2.10 45.2   53 NH 6 6.57 166.6 
22 10 11 2.11/2.10 33.2   54 NH 8 6.57 168.3 
23 10 7 2.11/2.10 96.1   55 NH 7 6.57 96.1 
24 11 9 2.21/2.20 45.2   56 NH 13 6.5 167.4 
25 11 10 2.21/2.20 19.6   57 NH 12 6.5 95.7 
26 11 7 2.21/2.20 96.1   58 NH 14 6.5 54.3 
27 11 8 2.21/2.20 168.3   59 NH 15 6.5 166.4 
28 18 12 2.33/2.31 95.7   60 NH 19 6.5 36.6 
29 18 13 2.33/2.31 167.4   61 14 15 4.26 167.4 
30 18 17 2.33/2.31 19.5   62 14 19 4.26 36.6 
31 18 16 2.33/2.31 44.7   63 14 22 4.26 15.8 
32 17 12 1.97/1.96 95.7   64 14 20 4.26 24 
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Table 9.  Annotated HMBC correlations of MAV-1(1). 
Actual signals noted within the HMBC spectrum 
 
Actual signals noted within the HMBC spectrum 
Theoretical Signal # 
Signal 
Coordinates 
Corresponding 
Carbons 
 
Theoretical Signal # 
Signal 
Coordinates 
Corresponding 
Carbons 
  X Y δH δC 
 
  X Y δH δC 
2 0.96 23.1 1 or 4 1 
 
30 2.31 19.5 18 17 
2 0.98 21.2 1 or 4 4 
 
31 2.31 44.8 18 16 
3 0.97 40.0 1 or 4 3 
 
32 1.97 95.7 17 12 
4 1.80 23.1 2 1 
 
33 1.94 33.1 17 18 
5 1.78 40.1 2 3 
 
33 1.99 33.1 17 18 
6 1.78 21.3 2 4 
 
35 3.71 33.1 16 18 
8 1.61 23.2 3 1 
 
36 3.71 19.5 16 17 
8 2.00 23.1 3 1 
 
38 2.31 167.3 19 15 
9 1.61 24.5 3 2 
 
38 2.34 167.3 19 15 
9 2.00 24.5 3 2 
 
39 2.32 24.0 19 20 
10 1.61 21.3 3 4 
 
40 2.30 12.0 19 21 
10 2.00 21.3 3 4 
 
41 2.32 15.8 19 22 
12 1.61 168.3 3 6 
 
42 1.20 12.0 20 21 
12 2.00 168.3 3 6 
 
42 1.33 12.0 20 21 
16 4.38 24.4 5 2 
 
44 1.20 36.6 20 19 
17 4.37 40.0 5 3 
 
44 1.33 36.6 20 19 
18 4.38 168.3 5 6 
 
45 1.20 15.6 20 22 
19 3.80 19.6 9 10 
 
45 1.33 15.8 20 22 
20 3.81 33.2 9 11 
 
46 0.90 36.5 21 19 
20 3.82 33.2 9 11 
 
47 0.90 24.0 21 20 
21 2.09 45.1 10 9 
 
49 1.06 36.5 22 19 
22 2.07 33.2 10 11 
 
50 1.06 23.9 22 20 
22 2.12 33.2 10 11 
 
51 6.48 61.0 NH(1) 5 
23 2.11 96.0 10 7 
 
54 6.48 166.5 NH(1) 8 
24 2.20 45.2 11 9 
 
56 6.55 166.4 NH (2) 13 
25 2.18 19.4 11 10 
 
57 6.54 95.8 NH (2) 12 
25 2.20 19.5 11 10 
 
58 6.54 54.1 NH (2) 14 
26 2.20 96.0 11 7 
 
61 4.27 167.3 14 15 
27 2.20 166.3 11 8 
 
63 4.27 15.7 14 22 
28 2.31 95.8 18 12 
       
 
 The structure presumed using the information gained by the Crews paper is well 
supported by the 2D NMR spectral data.  This further validates the presumed structure of MAV-
1 (1).  Confirmation of the structure would require x-ray crystallography. 
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While attempting to further purify MAV-1 (1) for bioassay and publication, the 1.5 mg 
isolated from the 5 L culture were lost or destroyed in reverse phase HPLC purification.  No 
other compounds isolated from K31A produced similar bioactivity as noted in the 100 mL 
culture.   
Despite repeating the culture numerous time under both similar and varied conditions, 
this compound was never again found.  Experiments necessary for solving the stereochemistry 
were not performed, and no more data on MAV-1 (1) can be obtained.   
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Conclusion 
 Though MAV-1 (1) was lost and not recovered, its presence is known.  It can be 
hypothesized that MAV-1 (1) is actually a precursor to several known compounds.  It is not 
plausible that MAV-1 (1) is an laboratory generated artifact of these known compounds as 
peroxides are inherently unstable and difficult to make in the laboratory setting.  Surprising is 
actually that the compound survived lyophilization, extraction by methanol, liquid 
chromatography, and air drying.   
 So, if indeed this is a precursor, the question to be asked is why this had never been found 
before?  The compounds that arise from MAV-1 (1) are well known, so it stands that the 
precursor has always been a secondary metabolite awaiting discovery.  Clearly, reproducibility 
for this methodology did not exist.  That is not the same as saying the methodology had no 
effect.  The metabolite profile of this organism was so enhanced that the precursor compound to 
known anti-microbial agents was visible for the first time.  A more stable and reproducible 
methodology must be found to insure the continued antibiotic pipeline.  Without this pipeline, 
these ever evolving organisms will continue to take human life at an unacceptable rate. 
Another stable peroxide, artemisinin, has a similar structure and ability to donate electron 
density across a majority of the compound.  This compound is famous for its anti-malarial 
activity.  It is possible that MAV-1 (1) could have similar anti-malarial activity.  The synthesis of 
MAV-1 (1) should be prioritized so as test this compound for useful activity.   
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